281 results about "Peg modification" patented technology

A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor / blood ratio of the polyethylene glycol containing compound.

The invention discloses a thiol-polyethylene glycol modified magneto-optical composite nano-material and its application. An up-conversion nano material is taken as a basal layer, the surface of the basal layer is provided with a polyacrylic acid layer, the surface of the polypropylene layer is provided with a layer of dopamine modified ferriferrous oxide magnetic particles, a golden shell layer is covered on the dopamine modified ferriferrous oxide magnetic particles layer, and the thioctic acid modified polyethylene glycol is provided on the golden shell layer; the thiol-polyethylene glycolmodified magneto-optical composite nano-material has guidance functions of up-conversion imaging and magnetic resonance imaging dual imaging, under the physical induction action of the magnetic field, the nano-material of the invention enables magnetic targeting to the specific position, so that the distribution in other internal organs can be reduced, and the damage in other internal organs during the treatment process is reduced. The nano-material can be taken as a good reagent for photo-thermal treatment by using the strong absorption property on the surface. The magnetic targeting photo-thermal treatment is combined under the imaging guidance, thereby the composite nano-material of the invention plays an important effect in clinical medical science and biological technology in future.

The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)α—[O—(CH2)β]γ—Oδ—(CH2)ε—Y—wherein α, β, γ, δ, and ε are each integers whose values are independently selected.

The invention provides a liposome-modified spermine derivative and a liposome prepared by the derivative. The spermine derivative is directly applied or is mixed with one or more selected from cholesterol, neutral lipids and polyethylene glycol (PEG)-modified lipids, which can be adopted as a carrier for entrapping or absorbing bioactive molecular drugs to be loaded into cells. In this way, the effect of regulation, intervention or treatment is realized. In a general formula (1), X1 represents -(CH2)- or carbonyl group, wherein n represents 1, 2 or 3; X2 represents -(CH2)-, ester group, amide group, oxygen, or sulfur; R1 and R2 independently represent C6-C18 alkyl group or lipophilic cholesterol molecules, respectively.

The invention relates to a series of polyethylene glycol modified cationic antibacterial peptide with different molecular weight. The modified antibacterial peptide is self-assembled into a nanometer micelle in an aqueous medium. The formation of the micelle can play a role in protecting the antibacterial peptide and weakening the degradation effect of protease on the antibacterial peptide, and simultaneously improves the stability and antibacterial activity of polypeptide in serum. In addition, the modification of polyethylene glycol obviously reduces the hemolytic toxic side effects of the antibacterial peptide.

The invention belongs to the field of new auxiliary materials and new dosage forms of medicine preparations and relates to a chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof. A chemotherapeutic drug is an anthracycline chemotherapeutic drug selected from mitoxantrone, doxorubicin or epirubicin; a photosensitizer is a porphyrin photosensitizer selected fromchlorine e6, hematoporphyrin monomethyl ether or a chlorophyll derivative, wherein the molar ratio of the chemotherapeutic drug to the photosensitizer is 3:1-1:3. A certain quantity of the chemotherapeutic drug and the photosensitizer or a mixture of the chemotherapeutic drug, the photosensitizer and PEG is dissolved in a proper quantity of organic solvent, and the solution is slowly dropwise added to water while stirring to form uniform nanoparticles spontaneously. The preparation process is simple, enlarged production is easy, particle size is small and uniform, and the nanoparticles can beenriched at tumor parts through a reinforced permeation retention effect; the nanoparticles have ultrahigh drug loading capacity and can reduce related toxicity of auxiliary materials; and surface modification is easy, and the circulation time of the nanoparticles in blood can be prolonged by PEG modification.

The invention discloses an RP-HPLC detection method for the content of free polyethylene glycol in samples or products, which is characterized by making use of the non-polar difference of polyethylene glycol from other substances on the reversed-phase chromatography column and using UV detector combining evaporative light detector or diode array detector combining evaporative light detector signal contrast to screen signal peaks of free polyethylene glycol and to determine the content thereof by means of the external standard method. Based on the method, the invention also can be used for detecting the purity of polyethylene glycol modified products and the modification degree of modified products. The analysis method is highly sensitive, good in repetitiveness and selectivity, fast, efficient and simple, and is suitable for being used in the samples which have more complex components and are interfered in the polyethylene glycol-barium compound colorimetric determination provided by pharmacopoeia, especially suitable for being used in the polyethylene glycol modified samples or products.

The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.

The invention discloses a preparation method of a tumor targeted photothermal therapy nanocarrier. The method comprises steps as follows: with GO as a carrier, loading MoS2 on GO with a hydrothermal method, and performing PEG modification to obtain the GO-MoS2 composite carrier. A composite of GO and MoS2 is taken as a phototherapeutic drug carrier for the first time, the preparation method is simple and convenient, and conditions are mild; the prepared GO-MoS2 drug-carrying composite has good photothermal conversion characteristic and higher drug carrying ratio which is higher than or equal to 80%. The drug release rate of the GO-MoS2 drug-carrying composite is 78% under laser power of 1.8 W / cm<2> in the presence of NIR laser. Compared with a conventional photothermal therapy nano-drug carrier, the GO-MoS2 drug-carrying composite has higher photo-thermal conversion rate due to synergistic effect of the two materials.

The invention relates to a method for preparing a multifunctional manganous manganic oxide nano-particle nuclear magnetic resonance contrast agent mediated by polyethyleneimine. The method comprises the following steps: preparing PEI modified Mn3O4 nano-particles by using a solvothermal method, and then separating and purifying the nano-particles; then, marking tracer molecule fluorescein isothiocyanate FI on the nano-particles; modifying polyethylene glycol PEG molecules on the amino of PEI; and finally, modifying targeted reagent folic acid FA molecules on the PEI through PEG modification and performing complete acetylation treatment to obtain the contrast agent. The contrast agent prepared in the invention can trace the phagocytosis condition of the cancer cells to nanoparticles in a cellular level, has a significant targeting function on a high-expression cancer cell strain of an FA receptor and can be used for achieving early diagnosis of cancer, meanwhile, since the preparation method of the contrast agent is simple and easy and the raw materials are cheap and easy to obtain, the contrast agent can be produced in large batches.

The invention provides a construction and modification method of recombinant porcine long-acting-alpha interferon and a preparation method of a lyophilized injection. Recombinant porcine-alpha interferon provided by the invention is prepared by adopting colon bacillus soluble expression, and the recombinant porcine long-acting-alpha interferon is obtained by using polyethylene glycol to perform modification according to the characteristics of polyethylene glycol, so that the half life of the recombinant porcine long-acting-alpha interferon in a pig body is prolonged to 44.5h and the porcine immunity is enhanced. The recombinant porcine long-acting-alpha interferon provided by the invention has excellent expression under high density and high volume of bacteria, production and purification processes are simple and novel, the cost is low, and the product yield and purity are improved. The lyophilized injection of the recombinant porcine long-acting-alpha interferon, provided by the invention, has the advantages of low cost, significant curative effect and stable product quality.